Tempus ECG-AF vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These tools are adjacent rather than direct competitors, as they address different cardiac conditions using distinct diagnostic inputs. Tempus ECG-AF utilizes 12-lead ECGs to identify patients at risk of atrial fibrillation, while Ultromics' EchoGo Amyloidosis analyzes echocardiogram video clips for the early detection of cardiac amyloidosis. Therefore, the choice between them depends entirely on the specific cardiac condition being screened for.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Tempus ECG-AF is an AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. Ultromics' EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis (CA).
Tempus ECG-AF analyzes 12-lead ECG recordings and is compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems. EchoGo Amyloidosis analyzes echocardiogram video clips, specifically requiring a single apical 4-chamber echo video clip.
Tempus ECG-AF is intended for patients 65 years or older without pre-existing atrial fibrillation/flutter, pacemakers, ICDs, or recent cardiac surgery. EchoGo Amyloidosis is indicated as a screening tool for adult patients aged 65 years and over with heart failure undergoing cardiovascular assessment using echocardiography.
Tempus ECG-AF has CMS reimbursement available via CPT 0764T and CPT 0765T, assigned to APC 5734, with a Medicare rate of $128.90, effective January 1, 2025. EchoGo Amyloidosis has inpatient reimbursement through NTAP Code ICD-10 XXE2X19 at $1,000 per analysis (Medicare-covered), and outpatient reimbursement via HCPCS Code C9786 at $285 per analysis, covered by Medicare and select commercial insurers.
Tempus ECG-AF detects signs associated with new onset Atrial Fibrillation (AF) within 12 months, with results interpreted in conjunction with other diagnostic information and clinical history. EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis based on its analysis of echocardiographic markers.
EchoGo Amyloidosis has high diagnostic accuracy, reporting 85% sensitivity and 93% specificity, with consistent performance across CA subtypes (AL, wild-type ATTR, variant ATTR). For Tempus ECG-AF, a positive result indicates that AF would be observed in approximately 1-in-5 patients within the next 12 months.